Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Survey to Evaluate the Effectiveness of Risk Minimisation Measures for Atezolizumab Use in the European Union Dr Flavia Di Nucci 05/02/2021
Finalised Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and subcutaneous formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries Dr Nawab Qizilbash, MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 21/08/2019
Finalised Evaluation of the effectiveness of Penthrox® (methoxyflurane) educational tools adopted as additional risk minimisation measures: Healthcare professional and Patient Survey. Dr Nawab Qizilbash 03/05/2019
Finalised Localised Neuropathic Pain (LNP) managed in the primary care setting in France, Ireland, Italy, Spain, and the United Kingdom: A cross-sectional study of prevalence, clinical characteristics, treatment patterns and patient’s reported outcomes Dr Nawab Qizilbash 28/08/2018
Finalised Evaluation of the effectiveness of the belatacept (Nulojix®) Patient Alert Card in patients following renal transplantation in European Economic Area countries. Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 15/02/2018
Finalised Disease progression and resource utilization in treated relapse/refractory multiple myeloma in Spain Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 27/10/2017
Finalised Myozyme (alglucosidase alfa) Safety Information Packet effectiveness evaluation: a health care professional survey Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 24/05/2017
Ongoing A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza infection Professor GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor 19/11/2021
Ongoing A retrospective study to evaluate the clinical effectiveness and safety of treatments for Covid-19 hospitalised patients and to determine prognostic factors. Dr Nawab Qizilbash MRCP DPhil(Oxon) 24/06/2020
Ongoing Real-time systematic review and meta-analysis of non-randomised comparative treatment studies for COVID-19 Dr Nawab Qizilbash MRCP MSc DPhil(Oxon) 24/06/2020
Ongoing Post Authorisation Safety Study (PASS) to Evaluate the Risks of Hepatotoxicity and Nephrotoxicity from Administration of Methoxyflurane (Penthrox®) for Pain Relief in Hospital Accident & Emergency Departments in the United Kingdom Professor Nawab Qizilbash 07/08/2019
Ongoing Longitudinal Analyses of Body Mass Index and Risk of Parkinson's Disease in 2 million people over 2 decades Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 04/04/2018
Ongoing Systematic Review and meta-analysis of PASS Studies Assessing the Effectiveness of Risk Minimisation Measures Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 02/04/2018
Planned Zanamivir 10mg/ml solution for infusion pregnancy registry: an observational study of the safety of zanamivir 10mg/ml solution for infusion exposure in pregnant women with complicated influenza and their offspring Professor GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor 21/10/2021
Planned Longitudinal Analyses of Blood Lipids and Future Risk of Dementia in CPRD Professor Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 30/04/2021
Planned Non-interventional study with Binosto 70 mg effervescent tablets once weekly investigating gastro-intestinal events and medication errors Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 06/02/2020
Planned Longitudinal Analyses of Blood Pressure and Risk of Alzheimer´s disease and Vascular Dementia in 2.6 million people over 2 decades Professor Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 12/05/2018
Planned Characterising the safety profile of lurasidone in clinical practice: A drug utilisatio and safety study using a United Kingdom primary care database Dr Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) 07/04/2017
Planned Retrospective Cohort Study of Certolizumab Pegol (Cimzia®) and Other Subcutaneous Anti-Tumour Necrosis Factor-Alpha Drugs in Rheumatoid Arthritis to Explore Usage Patterns and Clinical Outcomes in daily clinical practice in the United Kingdom Professor Costantino Pitzalis 11/01/2013